ABIOMED Inc.

330.00-3.11-0.93%Vol 81.18K1Y Perf 111.07%
Apr 13th, 2021 14:40 DELAYED
BID329.63 ASK330.19
Open334.13 Previous Close333.11
Pre-Market- After-Market-
 - -%  - -
Target Price
378.00 
Analyst Rating
Moderate Buy 2.19
Potential %
14.61 
Finscreener Ranking
★★★     49.46
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★     52.54
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     75.83
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap14.93B 
Earnings Rating
Sell
Price Range Ratio 52W %
75.12 
Earnings Date
29th Apr 2021

Today's Price Range

329.28336.77

52W Range

156.67387.40

5 Year PE Ratio Range

21.20260.10

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
2.93%
1 Month
9.74%
3 Months
2.90%
6 Months
20.28%
1 Year
111.07%
3 Years
12.26%
5 Years
237.94%
10 Years
1 997.67%

TickerPriceChg.Chg.%
ABMD330.00-3.1100-0.93
AAPL134.463.22002.45
GOOG2 265.4510.66000.47
MSFT258.102.19000.86
XOM55.650.15000.27
WFC39.79-0.9800-2.40
JNJ159.19-2.4500-1.52
FB312.100.56000.18
GE13.48-0.1100-0.81
JPM154.45-1.5000-0.96
ProfitabilityValueIndustryS&P 500US Markets
80.90
27.70
30.50
28.60
27.82
RevenueValueIndustryS&P 500US Markets
606.28M
13.40
3.97
17.53
Earnings HistoryEstimateReportedSurprise %
Q03 20211.151.171.74
Q02 20210.871.0116.09
Q01 20210.210.58176.19
Q04 20200.961.004.17
Q03 20201.091.111.83
Q02 20200.931.0310.75
Q01 20200.991.001.01
Q04 20191.071.070.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR1.10-1.79Negative
3/2021 FY3.872.38Positive
6/2021 QR1.08-0.92Negative
3/2022 FY4.81-1.23Negative
Next Report Date29th Apr 2021
Estimated EPS Next Report1.10
Estimates Count6
EPS Growth Next 5 Years %16.00
Volume Overview
Volume81.18K
Shares Outstanding45.23M
Trades Count2.96K
Dollar Volume103.09M
Avg. Volume323.61K
Avg. Weekly Volume162.56K
Avg. Monthly Volume267.53K
Avg. Quarterly Volume324.80K

ABIOMED Inc. (NASDAQ: ABMD) stock closed at 333.11 per share at the end of the most recent trading day (a -0.21% change compared to the prior day closing price) with a volume of 169.12K shares and market capitalization of 14.93B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 1536 people. ABIOMED Inc. CEO is Michael R. Minogue.

The one-year performance of ABIOMED Inc. stock is 111.07%, while year-to-date (YTD) performance is 2.75%. ABMD stock has a five-year performance of 237.94%. Its 52-week range is between 156.67 and 387.4, which gives ABMD stock a 52-week price range ratio of 75.12%

ABIOMED Inc. currently has a PE ratio of 75.10, a price-to-book (PB) ratio of 11.82, a price-to-sale (PS) ratio of 24.85, a price to cashflow ratio of 54.70, a PEG ratio of 2.32, a ROA of 14.68%, a ROC of 17.37% and a ROE of 16.70%. The company’s profit margin is 27.82%, its EBITDA margin is 30.50%, and its revenue ttm is $606.28 Million , which makes it $13.40 revenue per share.

Of the last four earnings reports from ABIOMED Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.10 for the next earnings report. ABIOMED Inc.’s next earnings report date is 29th Apr 2021.

The consensus rating of Wall Street analysts for ABIOMED Inc. is Moderate Buy (2.19), with a target price of $378, which is +14.61% compared to the current price. The earnings rating for ABIOMED Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ABIOMED Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ABIOMED Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.81, ATR14 : 15.31, CCI20 : 138.17, Chaikin Money Flow : 0.19, MACD : -5.18, Money Flow Index : 72.17, ROC : 13.22, RSI : 39.05, STOCH (14,3) : 96.08, STOCH RSI : 0.39, UO : 64.57, Williams %R : -3.92), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ABIOMED Inc. in the last 12-months were: Andrew J. Greenfield (Option Excercise at a value of $662 500), Andrew J. Greenfield (Sold 34 312 shares of value $11 104 551 ), Dorothy E. Puhy (Sold 35 000 shares of value $9 622 347 ), Martin P. Sutter (Option Excercise at a value of $239 760), Martin P. Sutter (Sold 37 500 shares of value $8 494 765 ), Paul G. Thomas (Sold 4 000 shares of value $1 213 640 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (44.44 %)
4 (44.44 %)
4 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (44.44 %)
4 (44.44 %)
3 (37.50 %)
Moderate Sell
1 (11.11 %)
1 (11.11 %)
1 (12.50 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.19
Moderate Buy
2.19
Moderate Buy
2.09

ABIOMED Inc.

Abiomed Inc provides temporary mechanical circulatory support devices that are primarily used by interventional cardiologists and heart surgeons. The firm's products are used for patients in need of hemodynamic support before, during, or after angioplasty and heart surgery procedures. Abiomed receives the majority of revenue from its Impella product portfolio, which includes percutaneous micro heart pumps with integration motors and sensors and percutaneous catheter-based axial flow pumps. Abiomed generates the majority of its revenue in the United States.

CEO: Michael R. Minogue

Telephone: +1 978 646-1400

Address: 22 Cherry Hill Drive, Danvers 01923, MA, US

Number of employees: 1 536

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

61%39%

Bearish Bullish

58%42%

Bearish Bullish

57%43%

News

Stocktwits